Study:
Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva
Rationale:
n/a
Purpose:
The purpose of this study is to investigate the efficacy of Raptiva (efalizumab) in the
treatment of discoid lupus erythematosus (DLE). Discoid lupus erythematosus is a chronic
disorder, which may lead to permanent and progressive loss of hair. Lupus is a condition of
chronic inflammation cause by an autoimmune disease. Autoimmune diseases are illnesses which
occur when the body`s tissues are attacked by its own immune system. The immune system is a
complex system within the body that is designed to fight infectious agents, for example,
bacteria, and other foreign invaders.
One of the mechanisms that the immune system uses to fight infections is the production of
antibodies. Patients with lupus produce abnormal antibodies in their blood that target
tissues within their own body rather than foreign infectious agents. Lupus can cause disease
of the skin, heart, lungs, kidneys, joints, and nervous system. When only the skin is
involved, the condition is called discoid lupus erythematosus (DLE).
Raptiva (efalizumab) is a humanized immunoglobulin(a protein extract from blood which fights
off infection-sometimes called "antibody"), which targets the immune cells that are activated
in inflammation. Raptiva has been approved for use in the management of psoriasis at doses
of 1mg/kg, but is not approved for the treatment of DLE.
Study Status: Terminated
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Discoid Lupus Erthematosus of the Scalp. |
Drug: Raptiva (efalizumab) |
Phase 2 |
Verified by
The Cleveland Clinic
May, 2007
Sponsored by: The Cleveland Clinic
Information provided by: The Cleveland Clinic
ClinicalTrials.gov identifier: NCT00308204
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Cleveland Clinic
Cleveland, Ohio 44195
United States
Wilma F Bergfeld, MD., Principal Investigator